1-3 of 3
Jacy Spong
Close
Sort by
Journal Articles

Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma

Craig B. Reeder, MD, Donna E. Reece, MD, Vishal Kukreti, MD, FRCPC, Joseph Mikhael, MD, Christine I. Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Giovani Piza, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Jose F Leis, MD, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Jacy Spong, BS, RN, BSN, Angela Mayo, PA/NP, Keith Stewart, MD
Journal: Blood
Blood (2013) 122 (21): 3192.
https://doi.org/10.1182/blood.V122.21.3192.3192
Published: 2013
Journal Articles

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Brief Report
Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. Reeder, A. Keith Stewart, P. Leif Bergsagel, Rafael Fonseca
Journal: Blood
Blood (2012) 119 (19): 4391–4394.
https://doi.org/10.1182/blood-2011-11-390930
Published: 2012
Journal Articles

The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis

Joseph R. Mikhael, MD, Steven R. Schuster, MD, Victor H Jimenez-Zepeda, MD, PD, Nancy Bello, Jacy Spong, Craig B. Reeder, MD, A. Keith Stewart, MD, P.Leif Bergsagel, MD, Rafael Fonseca
Journal: Blood
Blood (2010) 116 (21): 3063.
https://doi.org/10.1182/blood.V116.21.3063.3063
Published: 2010